Price Chart

DATE TIME TYPE PERIOD REPORTED
EPS
ESTIMATED
EPS
SURPRISE
11/11/2022* -- Results Q3 2022 -- 1.13 --
11/11/2022* 08:30 EST Earnings Call Q3 2022 -- -- --
08/04/2022 -- Results Q2 2022 1.25 1.19 4.67%
08/04/2022 08:30 EST Earnings Call Q2 2022 -- -- --
05/05/2022 -- Results Q1 2022 1.65 1.30 26.70%
05/05/2022 08:30 EST Earnings Call Q1 2022 -- -- --
02/17/2022 -- Results Q4 2021 1.37 1.27 7.68%
02/17/2022 08:30 EST Earnings Call Q4 2021 -- -- --
*Estimated Date/Time

Earnings

Next Report Date 11/11/2022 (est.)
EPS Estimate Upgrade
Last Actual EPS Upgrade

Loading chart...
Last Report Date 08/04/2022
Beat/Miss Upgrade
Return Since -19.96%
Last FQE 06/30/2022
Next FQE 09/30/2022

Profile

Edit
Organon & Co is a science-based global pharmaceutical company that develops and delivers health solutions through a portfolio of prescription therapies within women's health, biosimilars, and established brands. Geographically, it derives a majority of revenue from Europe and Canada.
URL https://www.organon.com
Investor Relations URL N/A
HQ State/Province New Jersey
Sector Healthcare
Industry Drug Manufacturers - General
Equity Style Mid Cap/Value
Next Earnings Release Nov. 11, 2022 (est.)
Last Earnings Release Aug. 04, 2022
Next Ex-Dividend Date N/A
Last Ex-Dividend Date Aug. 12, 2022

Dividends

Dividend Per Share (TTM) 1.12
2017
2018
2019
2020
2021
No data available
 
6.00%
4.00%
2.00%
 
Yield to Market 2.966
Yield to Sector 2.361
Yield to Industry 1.178
Last Dividend Amt. 0.28
Dividend Frequency Quarterly
Last Ex-Dividend Date Aug. 12, 2022
Yield (TTM) 4.36%
Forward Yield 4.36%
Payout Ratio 26.02%
Cash Payout Ratio 83.96%
Consistent Payer (5Y) No
Consistent Growth (5Y) No

Ownership

Insider Ownership Percentage Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Short Interest

Short Interest Upgrade
Percent of Shares Outstanding Short Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Total Returns Comparison

Edit comparables

Annual Total Returns Versus Peers

Edit comparables
Loading chart...
Name
2015
2016
2017
2018
2019
2020
2021
YTD
--
--
--
--
--
--
--
-13.48%
1.38%
11.96%
21.83%
-4.38%
31.49%
18.40%
28.71%
-19.50%
-3.72%
15.23%
-1.33%
40.20%
22.42%
-7.07%
1.86%
18.24%
-87.17%
63.37%
16.67%
-79.93%
-17.17%
8.91%
-45.97%
-71.32%
-9.04%
-23.93%
70.05%
-17.52%
10.42%
-13.60%
-24.30%
-51.92%
-18.25%
-29.46%
-55.16%
-57.46%
-66.95%
321.7%
-47.71%
-67.81%
As of October 04, 2022.

Profile

Edit
Organon & Co is a science-based global pharmaceutical company that develops and delivers health solutions through a portfolio of prescription therapies within women's health, biosimilars, and established brands. Geographically, it derives a majority of revenue from Europe and Canada.
URL https://www.organon.com
Investor Relations URL N/A
HQ State/Province New Jersey
Sector Healthcare
Industry Drug Manufacturers - General
Equity Style Mid Cap/Value
Next Earnings Release Nov. 11, 2022 (est.)
Last Earnings Release Aug. 04, 2022
Next Ex-Dividend Date N/A
Last Ex-Dividend Date Aug. 12, 2022

Ownership

Insider Ownership Percentage Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Short Interest

Short Interest Upgrade
Percent of Shares Outstanding Short Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Top Fund Holders

Symbol Dollars Invested % Weight
JCNIX 181.85M USD 4.23%
CSD 2.259M USD 4.20%
FTXH 1.342M USD 3.60%
JORIX 69.27M USD 3.24%
XPH 5.947M USD 2.88%
LMCQX 30.45M USD 2.61%
IHE 9.537M USD 2.48%
LAVTX 39.93M USD 2.22%
PPH 9.960M USD 1.87%
LAFQX 101.11M USD 1.80%
SVFCX 32.96M USD 0.84%
EZM 4.339M USD 0.66%

Top Portfolio Holders

0 of 0

Other Resources

Whale Wisdom 13F Filings
Seeking Alpha Call Transcripts
Morningstar Insider Trading
Nasdaq Institutional Ownership
Nasdaq Option Chain
SEC SEC Filings
Twitter OGN Tweets